RARE Historical PE Ratio Notes

— Ultragenyx Pharmaceutical (RARE) is a biopharmaceutical company focused on developing & commercializing novel products for rare & ultra-rare genetic diseases. Unlike larger pharmaceutical firms, Ultragenyx operates in high-risk, high-reward markets that offer significant pricing power but also volatile earnings, as approvals, product launches, & the small size of target patient populations can dramatically impact revenue from year to year. As you review RARE's historical PE ratio, it’s important to note that, due to the company’s research-intensive phase & ongoing investment in clinical trials, Ultragenyx has often reported negative earnings or minimal profits, resulting in a high or even undefined PE ratio in many periods. This is typical among innovative biotech firms where stock price often reflects future growth expectations more than near-term profitability. When you examine the charts & tables of RARE's historical price, earnings, & PE ratio, consider how clinical trial results, regulatory milestones, & commercial launches of new therapies have caused sharp movements, as investors adjust their expectations for earnings potential and long-term growth. This context is essential for accurately interpreting historical valuation metrics for a dynamic company like Ultragenyx.

On this page we presented the Ultragenyx Pharmaceutical Historical PE Ratio information for Ultragenyx Pharmaceutical' stock. The average RARE historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average RARE historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this RARE historical PE result, against the recent PE: when this page was posted on 6/5/2026, the most recent closing price for RARE had been 21.91, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on RARE or any other given stock, valuation analysis for RARE can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Ultragenyx Pharmaceutical PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for RARE. Thanks for visiting, and the next time you need to research RARE Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.